Logo

OliX Receives Government Grant to Develop Anti-scarring Drug

Dec 12, 2014 | staff reporter
Premium

NEW YORK (GenomeWeb) — South Korea's OliX Pharmaceuticals announced that it has received an undisclosed amount of funding from the South Korean government to support the preclinical development of its siRNA-based anti-scarring drug candidate BMT 101.

The drug is designed to silence connective tissue growth factor, which is implicated in scarring and fibrosis. Notably, RXi Pharmaceuticals' Phase II anti-scarring drug RXI-109 is also designed to inhibit this target.

"Based on successful preclinical results, we are looking forward to proceeding with international licensing-outs of BMT101 to multinational companies for the entry of mature markets like the US, Europe, and Japan," OliX CEO Sun-Woo Hong said in a statement.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Drug Discovery & Development
scarring
RNAi
Breaking News
The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.